Oncolytic Virus Therapy Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others), By Application (Solid Tumors, Hematological Malignancies), by End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), by
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationOncolytic Virus Therapy Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others), By Application (Solid Tumors, Hematological Malignancies), by End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), by
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD15.38 billion |
| CAGR (2023-2028) | 23.10% |
| Fastest Growing Segment | Herpes Simple Virus (HSV) |
| Largest Market | North America |
Market Overview
Global Oncolytic Virus Therapy Market was valued at USD 15.38 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 23.10% through 2028. Oncolytic viruses are a class of viruses that can infect and selectively replicate in cancer cells, leading to their destruction or causing them to undergo programmed cell death (apoptosis). These viruses are engineered or naturally occurring to exhibit a tumor-selective preference, meaning they have an innate ability to target and replicate within cancerous cells while sparing normal, healthy cells. Oncolytic viruses have gained attention and significance in the field of cancer therapy due to their potential as a targeted and innovative treatment approach. Oncolytic viruses have an inherent preference for infecting and replicating within cancer cells. This selectivity is often based on differences in cellular factors and molecular characteristics between cancer cells and healthy cells. Once inside cancer cells, oncolytic viruses replicate and multiply. This replication eventually leads to the lysis (bursting) of the cancer cell, releasing newly formed viral particles that can infect adjacent cancer cells. This process continues, effectively spreading the infection throughout the tumor.
Ongoing research has deepened our understanding of oncolytic viruses, leading to the development of more potent and targeted therapies. This scientific progress drives innovation in the field. Positive outcomes in clinical trials and real-world applications of oncolytic virus therapies for various cancer types have boosted confidence in their efficacy. Demonstrating survival benefits and improved outcomes for patients has been a key driver. The concept of combining oncolytic virus therapy with other treatment modalities, such as immunotherapies or targeted therapies, has gained traction. This combination approach enhances the potential for better cancer treatment outcomes. Increased awareness and education about oncolytic virus therapy among healthcare professionals, patients, and the public have contributed to its acceptance and adoption.
Key Market Drivers
Advancements in Research
Researchers have made significant progress in genetically engineering oncolytic viruses to enhance their tumor-selectivity and therapeutic effectiveness. This includes modifying the virus's ability to replicate in cancer cells while sparing healthy cells. Combining oncolytic virus therapy with other cancer treatments, such as immunotherapies (e.g., immune checkpoint inhibitors) and targeted therapies, has shown promise in improving overall treatment outcomes. Researchers are exploring the best combinations and treatment sequences. Research efforts have led to the development of safer oncolytic viruses with reduced potential for off-target effects. Safety is a critical consideration in regulatory approval and clinical use. The human immune system can neutralize oncolytic viruses. Researchers are developing strategies to evade the host immune response or to enhance the immunostimulatory effects of oncolytic viruses, making them more effective in combating cancer.
Identifying biomarkers that can predict a patient's response to oncolytic virus therapy is a key area of research. This enables a more personalized approach to treatment and ensures that therapy is administered to those who are most likely to benefit. Research has led to innovations in the delivery of oncolytic viruses to tumor sites. This includes the use of nanoparticles, viral vectors, and specialized delivery vehicles to enhance the efficiency of virus delivery. While the Herpes Simplex Virus (HSV) has been prominent, research has expanded to include other virus platforms, such as adenoviruses, reoviruses, and poxviruses. Exploring a variety of virus platforms broadens the scope of oncolytic virus therapy. Ongoing clinical trials have explored the use of oncolytic virus therapy in various cancer types and at different stages of disease. These trials provide valuable data on safety and efficacy, helping to refine treatment protocols.
Researchers are developing methods to stratify patients based on their molecular and genetic profiles, enabling the tailoring of oncolytic virus therapy to individual patients. This personalized approach is considered a significant advancement. Some tumors develop resistance to oncolytic virus therapy over time. Research is ongoing to understand the underlying resistance mechanisms and to develop strategies to overcome them. Advances in the large-scale production and manufacturing of oncolytic viruses have made these therapies more accessible for clinical use. Research is uncovering new applications for oncolytic virus therapy, such as its use in combination with surgery or radiation therapy, as well as its potential in the treatment of rare cancers. This factor will help in the development of the Global Oncolytic Virus Therapy Market.
Increasing Awareness and Education
As patients become more informed about oncolytic virus therapy, they can actively engage in discussions with their healthcare providers and explore treatment options that best suit their needs. This empowerment can lead to increased demand for oncolytic virus therapy. Education and awareness efforts target healthcare professionals, ensuring that they are well-informed about oncolytic virus therapy. When doctors are aware of and understand the therapy, they are more likely to recommend it to eligible patients, thereby driving demand. Increased awareness of oncolytic virus therapy often leads to more patients participating in clinical trials. This not only advances research but also allows patients early access to promising therapies, driving demand in the experimental and post-approval stages. Patient advocacy organizations and support groups for cancer patients often play a role in raising awareness about oncolytic virus therapy. They may advocate for increased research funding, access to therapies, and education for patients and caregivers.
Media coverage, including news stories, documentaries, and social media discussions, can help spread the word about oncolytic virus therapy and its potential benefits. This increased visibility can generate interest and demand. Pharmaceutical companies, healthcare institutions, and nonprofit organizations often conduct educational campaigns to inform the public about oncolytic virus therapy. These campaigns aim to dispel myths, clarify the benefits, and promote the therapy's availability. Medical conferences and workshops are platforms for researchers, clinicians, and industry experts to share the latest developments in oncolytic virus therapy. This knowledge transfer helps disseminate information and promotes its adoption. Education can lead to advocacy for supportive healthcare policies, including reimbursement and coverage by health insurance providers. When oncolytic virus therapy is financially accessible to patients, demand is likely to increase.
Educational initiatives often extend to local communities, raising awareness about cancer treatment options. Community outreach programs may encourage patients to discuss oncolytic virus therapy with their healthcare providers. Awareness campaigns and education can help spread the knowledge of oncolytic virus therapy globally, potentially increasing demand in regions where it is less widely known or accessible. Public awareness can lead to increased research funding, which, in turn, supports the development of new and improved oncolytic virus therapies. More treatment options can drive demand. Hearing success stories and testimonials from patients who have benefited from oncolytic virus therapy can be powerful motivators for others to consider this treatment option. This factor will pace up the demand of the Global Oncolytic Virus Therapy Market.
Diverse Applications
Oncolytic virus therapy is not limited to specific cancer types. It can be applied to a wide range of malignancies, including solid tumors (e.g., melanoma, lung, breast, and colorectal cancers) and hematological cancers (e.g., leukemia and lymphoma). This broad spectrum of applications means that more patients can potentially benefit from oncolytic virus therapy. Oncolytic virus therapy can be used in combination with other treatment modalities, such as chemotherapy, radiation therapy, immunotherapies (e.g., immune checkpoint inhibitors), and targeted therapies. The synergy achieved through combination therapies can enhance treatment outcomes, and this versatility drives demand. Oncolytic virus therapy is not restricted to a particular stage of cancer. It can be used in early-stage cancers as part of curative treatment or in late-stage and recurrent cancers to improve palliative care and extend survival. This flexibility increases the therapy's appeal to both patients and healthcare providers. Some oncolytic virus therapies have shown promise in treating rare and less common cancers. For patients with these conditions, oncolytic virus therapy can represent a novel and potentially more effective treatment option. Oncolytic virus therapy can be applied to localized tumors as well as to tumors that have metastasized to other parts of the body. This dual capability makes it suitable for a wide range of clinical scenarios.
In some cases, oncolytic virus therapy can be administered before or after surgery, acting as neoadjuvant or adjuvant therapy to improve the outcome of surgical interventions. This versatility contributes to its demand. For patients with advanced cancer who may not have curative treatment options, oncolytic virus therapy can be used in palliative care to improve quality of life and extend survival. Diverse applications encourage research and clinical trials in various cancer settings. Ongoing studies and expanded applications provide data that supports the therapy's effectiveness and drive demand. Researchers are exploring the use of oncolytic virus therapy to target specific cancer subtypes with unique characteristics. This precision approach is appealing for patients with such subtypes. The ability to tailor oncolytic virus therapy to individual patients based on their genetic and molecular profiles aligns with the trend of personalized medicine, increasing its demand. This factor will accelerate the demand of the Global Oncolytic Virus Therapy Market.
Key Market Challenges
Efficacy and Safety Concerns
Efficacy can vary among different patients and cancer types. Not all patients respond equally to oncolytic virus therapy, and identifying predictors of response is an ongoing challenge. Tumors are biologically diverse, and this heterogeneity can affect the ability of oncolytic viruses to target and destroy cancer cells effectively. Adapting therapies to address tumor heterogeneity remains a challenge. The tumor microenvironment can be immunosuppressive, hindering the immune system's response to oncolytic viruses. Strategies to overcome immunosuppression are under investigation. Ensuring that oncolytic viruses specifically target cancer cells while sparing healthy tissue is a safety concern. Reducing off-target effects and minimizing collateral damage is a research priority. Tumors can develop resistance to oncolytic virus therapy over time, limiting its long-term effectiveness. Understanding and mitigating resistance mechanisms is a complex challenge. Safety concerns arise from the potential for oncolytic viruses to cause adverse events. Balancing the need for a potent antitumor effect with acceptable safety profiles is a delicate balance.
Manufacturing Complexity
Oncolytic viruses are biologically complex agents that require specialized conditions for growth, propagation, and purification. Their large size, genetic diversity, and replication requirements add to the intricacy of manufacturing. The manufacturing process must adhere to strict sterility standards to prevent contamination, as oncolytic viruses are highly sensitive to contaminants that could compromise their safety and efficacy. Ensuring that each batch of oncolytic viruses is consistent in terms of quality, potency, and safety is essential. Variability in production can lead to unpredictable treatment outcomes. Transitioning from small-scale laboratory production to large-scale manufacturing for clinical or commercial use is challenging. Scaling up the process while maintaining product quality and safety is complex. Specialized equipment and facilities are required to produce oncolytic viruses. These facilities must meet stringent regulatory and quality standards, which can be costly to establish and maintain. Purifying oncolytic viruses from the culture medium can be challenging due to their size and biological properties. Developing efficient purification methods that yield high-quality products is a manufacturing hurdle.
Key Market Trends
Diverse Virus Platforms
Different virus platforms have unique mechanisms of tumor selectivity, replication kinetics, and host interactions. Researchers are studying these properties to optimize each platform for specific cancer types and patient populations. Combining different virus platforms with one another or with other cancer treatments, such as immunotherapies or targeted therapies, is a growing trend. These combinations offer the potential for enhanced therapeutic effects and expanded applications. The diversity of virus platforms allows for a more personalized approach to treatment. By selecting the most suitable virus platform based on a patient's cancer characteristics, oncolytic virus therapy can be tailored to individual needs. The use of diverse virus platforms can help overcome challenges related to resistance mechanisms that tumors may develop against a particular virus. By switching to a different virus platform, clinicians can potentially re-sensitize the tumor to therapy. Different virus platforms come with varying safety profiles. Researchers aim to identify platforms that minimize off-target effects and adverse events while maximizing antitumor effects. The choice of virus platform can influence the method of delivery, such as intratumoral injection, intravenous administration, or targeted delivery systems. These strategies are designed to enhance virus distribution and tumor penetration.
Segmental Insights
Virus Type Insights
In 2022, the Global Oncolytic Virus Therapy Market largest share was held by Herpes Simplex Virus (HSV) segment and is predicted to continue expanding over the coming years.
Application Insights
In 2022, the Global Oncolytic Virus Therapy Market largest share was held by Malignancies segment and is predicted to continue expanding over the coming years.
End-User Insights
In 2022, the Global Oncolytic Virus Therapy Market largest share was held by
Regional Insights
The North America region dominates the Global Oncolytic Virus Therapy Market in 2022.
Recent Developments
- In November 2021, Clinicaltrial results from a Japanese phase 2 study involving GBM patients revealed aremarkable outcome – 92% of those who received Teserpaturev immunotherapy werestill alive after one year. This exceptional survival rate stands in starkcontrast to the conventional 15% one-year survival rate typically associatedwith standard late-stage brain tumor treatments, offering renewed hope to GBMpatients. In June 2021, Japan granted conditional and time-limited marketingapproval for Teserpaturev, the world's first oncolytic virus-basedimmunotherapy designed to treat glioblastoma (GBM), a malignant brain tumor.Teserpaturev, a genetically engineered herpes simplex virus type 1 (HSV-1), isnotable for its dual capability. Not only does it exhibit potent tumorcell-killing abilities within the brain, but it also effectively targets tumorcells that have metastasized to other regions of the brain. This uniquemechanism is achieved through the stimulation of systemic antitumor immunitywithin the patient's own immune system.
- In August 2022, CalidiBiotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company at theforefront of allogeneic cell-based platforms for advancing oncolytic virustherapies, was delighted to announce that City of Hope has received approvalfrom the U.S. Food and Drug Administration (FDA) to proceed with aphysician-sponsored phase 1 clinical trial. This trial will utilize Calidi'slicensed oncolytic virotherapy platform, NSC-CRAd-S-pk7 (known as NeuroNova), astate-of-the-art therapeutic candidate. NeuroNova comprises tumor-targetingneural stem cells designed to deliver an oncolytic adenovirus selectively totumor sites in patients with recurrent high-grade glioma, falling underCalidi's NNV-2 program. The upcoming phase 1physician-sponsored clinical trial is planned as an open-label, non-randomized,and multicenter study. Its primary focus, once funding is secured, will be toassess the safety and tolerability of administering consecutive doses of NeuroNovato adult patients with recurrent, histologically confirmed high-grade gliomas(classified as WHO grade III or IV).
Key Market Players
- Amgen Inc.
- Merck & Co., Inc.
- Oncolytics Biotech Inc.
- PsiOxus Therapeutics Ltd.
- Vyriad, Inc.
- SillaJen Biotherapeutics
- Cold Genesys Inc.
- Sorrento Therapeutics, Inc.
- Takara Bio Inc.
- Replimune Group Inc.
- Genelux Corporation
| By Virus Type | By Application | By End-User | By Region |
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy